Saturday 7 November 2026
Export ELAB’s income statement to Excel — free account
PMGC Holdings Inc.
ELAB Healthcare Biotechnology
PMGC Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $590,100.00, down 65.5% from fiscal 2023.
- Revenue
- +147.7%
- EPS
- +98.4%
- Free cash flow
- −45.0%
Quarter to June 2026, against a year earlier
1.61
0.04
−2.42%
Follow ELAB
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 3 |
+8 more TTM periods Free account |
| (104.60%) | (107.14%) | (106.89%) | (78.61%) | ||
| (58.71%) | (63.61%) | (70.88%) | (51.26%) | ||
ROIC |
0.00% | 0.00% | (220.80%) | 0.00% | |
Return on Tangible Assets |
(182.09%) | (162.38%) | (203.12%) | (141.82%) | |
Average Days of Receivables |
85.43 | 110.08 | 72.13 | 66.30 | |
Free Cash Flow per Share |
(18.44) | (188.12) | (1,675.24) | (2,993.68) | |
Free Cash Flow |
(8.99) | (8.37) | (6.38) | (6.59) | |
Capital Expenditures |
(0.78) | (0.81) | (0.45) | (0.40) | |
| Other line items | |||||
Cash ROIC |
(25.11%) | (29.84%) | (45.93%) | (38.75%) | |
Accounts Receivable Turnover |
7.59 | 6.05 | 9.97 | 10.24 | |
Accounts Payable Turnover |
2.30 | 1.90 | 1.20 | 0.76 | |
Inventory Turnover |
1.85 | 1.61 | 1.35 | 2.17 | |
Average Days of Payables |
261.26 | 242.25 | 361.32 | 298.76 | |
Days of Inventory on Hand |
191.52 | 93.51 | 49.26 | 69.31 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
15.71% | 8.99% | 8.53% | 8.71% | |
Selling, General and Administrative Expense of Revenue |
187.68% | 200.67% | 141.59% | 103.21% | |
Share Based Compensation of Revenue |
8.01% | 2.66% | (1.11%) | 0.49% | |
Interest Coverage |
(9.07) | (12.49) | (26.71) | (77.66) | |
Operating CF/Net income |
0.61 | 0.68 | 0.77 | 0.92 | |
Depreciation/Fixed assets |
0.30 | 0.15 | 0.11 | 0.10 | |
Capex/Depreciation |
(1.36) | (2.99) | (4.64) | (9.99) | |
Revenue per Share |
5.29 | 40.44 | 452.26 | 924.32 | |
Operating CF per Share |
(16.83) | (170.02) | (1,557.56) | (2,811.14) | |
Capex per Share |
(1.61) | (18.10) | (117.67) | (182.55) | |
Capex to Sales |
0.30 | 0.45 | 0.26 | 0.20 |
Columns are period end dates · fundamentals updated 26 Oct 2026